Tags

Type your tag names separated by a space and hit enter

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.

Abstract

INTRODUCTION

To assess the comparative effectiveness of febuxostat and allopurinol in reducing serum urate (sUA) levels in a real-world U.S. managed care setting.

METHODS

This retrospective study utilized 2009 to 2012 medical and pharmacy claims and laboratory data from a large U.S. commercial and Medicare Advantage health plan. Study patients had at least one medical claim with a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement post-index prescription. Reduction in sUA was examined using propensity score-matched cohorts, matched on patient demographics (gender, age), baseline sUA, comorbidities, geographic region and insurance type.

RESULTS

The study sample included 2,015 patients taking febuxostat and 14,025 taking allopurinol. At baseline, febuxostat users had a higher Quan-Charlson comorbidity score (0.78 vs. 0.53; P <0.001), but similar age and gender distribution. Mean (standard deviation (SD)) sUA level following propensity score matching among treatment-naïve febuxostat vs. allopurinol users (n = 873 each) were: pre-index sUA, 8.86 (SD, 1.79) vs. 8.72 (SD, 1.63; P = 0.20); and post-index sUA, 6.53 (SD, 2.01) vs. 6.71 (SD, 1.70; P = 0.04), respectively. A higher proportion of febuxostat users attained sUA goals of <6.0 mg/dl (56.9% vs. 44.8%; P <0.001) and <5.0 mg/dl (35.5% vs. 19.2%; P <0.001), respectively. Time to achieve sUA goals of <6.0 mg/dl (346 vs. 397 days; P <0.001) and <5.0 mg/dl was shorter in febuxostat vs. allopurinol users (431 vs. 478 days; P <0.001), respectively. Similar observations were made for overall propensity score-matched cohorts that included both treatment-naïve and current users (n = 1,932 each).

CONCLUSIONS

Febuxostat was more effective than allopurinol at the currently used doses (40 mg/day for febuxostat in 83% users and 300 mg/day or lower for allopurinol in 97% users) in lowering sUA in gout patients as demonstrated by post-index mean sUA level, the likelihood of and the time to achieving sUA goals.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Medicine Service and Center for Surgical Medical Acute care Research and Transitions (C-SMART), Birmingham VA Medical Center, 700 South 19th Street, Birmingham, AL, 35233, USA. jassingh@uab.edu. Department of Medicine at School of Medicine, University of Alabama, 1670 University Boulevard, Birmingham, AL, 35233, USA. jassingh@uab.edu. Division of Epidemiology at School of Public Health, University of Alabama, 1665 University Boulevard, Birmingham, AL, 35233, USA. jassingh@uab.edu. Department of Orthopedic Surgery, Mayo Clinic College of Medicine, 200 1st St SW, Rochester, MN, 55905, USA. jassingh@uab.edu. University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL, 35294, USA. jassingh@uab.edu.

    ,

    Takeda Pharmaceuticals International, Inc., One Takeda Parkway, Deerfield, IL, 60015, USA. kasem08a@msn.com.

    Takeda Pharmaceuticals International, Inc., One Takeda Parkway, Deerfield, IL, 60015, USA. aki.shiozawa@takeda.com.

    Source

    Arthritis research & therapy 17: 2015 May 12 pg 120

    MeSH

    Aged
    Allopurinol
    Cohort Studies
    Cost-Benefit Analysis
    Creatinine
    Dose-Response Relationship, Drug
    Drug Administration Schedule
    Febuxostat
    Female
    Gout
    Gout Suppressants
    Humans
    Male
    Managed Care Programs
    Medicare
    Reference Values
    Retrospective Studies
    Severity of Illness Index
    Treatment Outcome
    United States
    Uric Acid

    Pub Type(s)

    Comparative Study
    Journal Article
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    25963969

    Citation

    Singh, Jasvinder A., et al. "Comparative Effectiveness of Urate Lowering With Febuxostat Versus Allopurinol in Gout: Analyses From Large U.S. Managed Care Cohort." Arthritis Research & Therapy, vol. 17, 2015, p. 120.
    Singh JA, Akhras KS, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015;17:120.
    Singh, J. A., Akhras, K. S., & Shiozawa, A. (2015). Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Research & Therapy, 17, p. 120. doi:10.1186/s13075-015-0624-3.
    Singh JA, Akhras KS, Shiozawa A. Comparative Effectiveness of Urate Lowering With Febuxostat Versus Allopurinol in Gout: Analyses From Large U.S. Managed Care Cohort. Arthritis Res Ther. 2015 May 12;17:120. PubMed PMID: 25963969.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. AU - Singh,Jasvinder A, AU - Akhras,Kasem S, AU - Shiozawa,Aki, Y1 - 2015/05/12/ PY - 2014/08/06/received PY - 2015/04/14/accepted PY - 2015/5/13/entrez PY - 2015/5/13/pubmed PY - 2016/1/20/medline SP - 120 EP - 120 JF - Arthritis research & therapy JO - Arthritis Res. Ther. VL - 17 N2 - INTRODUCTION: To assess the comparative effectiveness of febuxostat and allopurinol in reducing serum urate (sUA) levels in a real-world U.S. managed care setting. METHODS: This retrospective study utilized 2009 to 2012 medical and pharmacy claims and laboratory data from a large U.S. commercial and Medicare Advantage health plan. Study patients had at least one medical claim with a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement post-index prescription. Reduction in sUA was examined using propensity score-matched cohorts, matched on patient demographics (gender, age), baseline sUA, comorbidities, geographic region and insurance type. RESULTS: The study sample included 2,015 patients taking febuxostat and 14,025 taking allopurinol. At baseline, febuxostat users had a higher Quan-Charlson comorbidity score (0.78 vs. 0.53; P <0.001), but similar age and gender distribution. Mean (standard deviation (SD)) sUA level following propensity score matching among treatment-naïve febuxostat vs. allopurinol users (n = 873 each) were: pre-index sUA, 8.86 (SD, 1.79) vs. 8.72 (SD, 1.63; P = 0.20); and post-index sUA, 6.53 (SD, 2.01) vs. 6.71 (SD, 1.70; P = 0.04), respectively. A higher proportion of febuxostat users attained sUA goals of <6.0 mg/dl (56.9% vs. 44.8%; P <0.001) and <5.0 mg/dl (35.5% vs. 19.2%; P <0.001), respectively. Time to achieve sUA goals of <6.0 mg/dl (346 vs. 397 days; P <0.001) and <5.0 mg/dl was shorter in febuxostat vs. allopurinol users (431 vs. 478 days; P <0.001), respectively. Similar observations were made for overall propensity score-matched cohorts that included both treatment-naïve and current users (n = 1,932 each). CONCLUSIONS: Febuxostat was more effective than allopurinol at the currently used doses (40 mg/day for febuxostat in 83% users and 300 mg/day or lower for allopurinol in 97% users) in lowering sUA in gout patients as demonstrated by post-index mean sUA level, the likelihood of and the time to achieving sUA goals. SN - 1478-6362 UR - https://www.unboundmedicine.com/medline/citation/25963969/full_citation L2 - https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-015-0624-3 DB - PRIME DP - Unbound Medicine ER -